Skip to main content

Table 3 1-, 2-, 5-, and 10-year incidence of bone metastases by tumor type and stage at diagnosis

From: Incidence of bone metastases in patients with solid tumors: analysis of oncology electronic medical records in the United States

Tumor type Incidence of bone metastases (%)
1-year (95% CI) 2-year (95% CI) 5-year (95% CI) 10-year (95% CI)
All tumor types combined (N = 382,733)
 Stage I (N = 54,305) 0.5 (0.4–0.5) 0.7 (0.7–0.8) 1.5 (1.4–1.6) 2.7 (2.4–2.9)
 Stage II (N = 47,080) 1.1 (1.0–1.2) 1.8 (1.7–1.9) 3.6 (3.4–3.8) 5.9 (5.6–6.3)
 Stage III (N = 35,289) 2.2 (2.0–2.3) 3.3 (3.1–3.5) 5.4 (5.1–5.6) 7.5 (7.1–8.0)
 Stage IV (N = 45,527) 18.0 (17.7–18.4) 20.3 (19.9–20.7) 23.7 (23.3–24.1) 27.6 (27.0–28.2)
Breast (N = 137,720)
 Stage I (N = 37,042) 0.3 (0.3–0.4) 0.5 (0.5–0.6) 1.2 (1.1–1.4) 2.4 (2.1–2.7)
 Stage II (N = 27,886) 1.0 (0.9–1.2) 1.8 (1.6–1.9) 3.9 (3.7–4.2) 6.5 (6.0–6.9)
 Stage III (N = 8720) 2.9 (2.6–3.3) 4.9 (4.4–5.3) 10.1 (9.4–10.8) 15.3 (14.1–16.5)
 Stage IV (N = 5985) 36.4 (35.2–37.7) 41.4 (40.2–42.7) 50.6 (49.3–52.0) 61.4 (59.5–63.2)
Prostate (N = 22,801)
 Stage I (N = 533) 3.0 (1.8–4.9) 4.4 (2.9–6.5) 7.7 (5.4–10.8) 12.1 (8.3–17.4)
 Stage II (N = 2737) 3.3 (2.6–4.0) 4.1 (3.4–4.9) 7.3 (6.3–8.4) 15.8 (12.0–20.6)
 Stage III (N = 591) 9.0 (6.9–11.6) 11.5 (9.2–14.4) 16.4 (13.4–19.9) 23.4 (18.7–29.0)
 Stage IV (N = 3908) 45.3 (43.8–46.9) 51.4 (49.9–53.0) 61.1 (59.5–62.8) 70.7 (68.4–72.9)
Lung (N = 59,344)
 Stage I (N = 4955) 1.4 (1.1–1.8) 2.3 (1.9–2.7) 3.6 (3.0–4.2) 5.1 (4.1–6.4)
 Stage II (N = 2603) 2.7 (2.2–3.4) 4.2 (3.4–5.0) 5.6 (4.7–6.7) 8.4 (6.9–10.4)
 Stage III (N = 7540) 4.4 (4.0–4.9) 5.8 (5.3–6.4) 6.7 (6.2–7.3) 7.4 (6.7–8.2)
 Stage IV (N = 13,487) 22.9 (22.2–23.6) 24.5 (23.8–25.3) 25.8 (25.1–26.6) 26.2 (25.4–27.0)
Colorectal (N = 46,832)
 Stage I (N = 2834) 0.2 (0.1–0.5) 0.4 (0.2–0.7) 1.0 (0.7–1.5) 1.6 (1.0–2.6)
 Stage II (N = 7105) 0.2 (0.1–0.3) 0.5 (0.3–0.7) 1.0 (0.7–1.3) 1.6 (1.1–2.2)
 Stage III (N = 9303) 0.4 (0.3–0.5) 0.7 (0.6–0.9) 1.5 (1.2–1.8) 1.9 (1.6–2.3)
 Stage IV (N = 7125) 3.0 (2.7–3.5) 4.1 (3.7–4.6) 5.8 (5.2–6.4) 6.6 (5.9–7.4)
Gastrointestinal (N = 32,874)
 Stage I (N = 1424) 0.4 (0.2–0.9) 0.7 (0.3–1.3) 1.5 (0.9–2.5) 2.2 (1.2–3.9)
 Stage II (N = 2998) 0.7 (0.5–1.1) 1.3 (0.9–1.7) 2.2 (1.7–2.9) 2.9 (2.0–4.1)
 Stage III (N = 2584) 1.2 (0.9–1.7) 1.9 (1.4–2.5) 2.7 (2.1–3.4) 2.9 (2.2–3.7)
 Stage IV (N = 5840) 5.3 (4.7–5.9) 6.1 (5.5–6.8) 6.8 (6.2–7.5) 7.4 (6.5–8.4)
Gynecological (N = 21,075)
 Stage I (N = 3922) 0.2 (0.1–0.4) 0.5 (0.3–0.8) 0.9 (0.6–1.3) 1.9 (1.1–3.2)
 Stage II (N = 1008) 0.6 (0.3–1.3) 1.0 (0.5–1.9) 1.8 (1.1–3.0) 2.0 (1.3–3.3)
 Stage III (N = 3012) 0.7 (0.4–1.0) 1.2 (0.9–1.7) 2.1 (1.6–2.8) 3.1 (1.9–5.1)
 Stage IV (N = 2076) 4.0 (3.3–5.0) 4.7 (3.8–5.7) 6.2 (5.2–7.5) 7.5 (5.9–9.6)
Malignant melanoma (N = 12,152)
 Stage I (N = 1581) 0.2 (0.1–0.6) 0.3 (0.1–0.7) 0.6 (0.3–1.3) 0.9 (0.4–1.7)
 Stage II (N = 822) 0.7 (0.3–1.6) 1.1 (0.6–2.1) 1.9 (1.1–3.3) 1.9 (1.1–3.3)
 Stage III (N = 877) 0.6 (0.2–1.4) 1.2 (0.6–2.1) 1.2 (0.6–2.1) 1.2 (0.6–2.1)
 Stage IV (N = 752) 6.1 (4.6–8.1) 7.4 (5.7–9.5) 9.0 (7.1–11.5) 10.4 (8.0–13.5)
Renal (N = 17,717)
 Stage I (N = 1654) 0.8 (0.5–1.4) 1.1 (0.7–1.8) 2.4 (1.7–3.4) 5.1 (3.4–7.6)
 Stage II (N = 1297) 1.5 (1.0–2.4) 2.4 (1.7–3.4) 3.9 (2.9–5.3) 5.0 (3.5–7.1)
 Stage III (N = 1210) 2.1 (1.5–3.1) 3.3 (2.4–4.5) 5.0 (3.8–6.5) 6.8 (5.1–9.1)
 Stage IV (N = 2668) 15.5 (14.2–16.9) 18.3 (16.9–19.8) 22.3 (20.7–24.1) 26.2 (23.6–29.0)
Other Tumors (N = 162,868)
 Stage I (N = 360) 0.8 (0.3–2.6) 1.7 (0.8–3.7) 2.1 (1.0–4.4) 5.2 (1.6–16.3)
 Stage II (N = 624) 0.8 (0.3–1.9) 1.3 (0.7–2.6) 3.2 (2.0–5.3) 4.8 (2.9–7.8)
 Stage III (N = 1452) 0.8 (0.4–1.4) 1.5 (1.0–2.3) 1.9 (1.3–2.8) 3.5 (2.1–5.7)
 Stage IV (N = 3686) 2.7 (2.2–3.3) 3.8 (3.2–4.5) 4.6 (4.0–5.4) 5.3 (4.3–6.4)